Azacitidine — Drug Monograph

Brand names: Vidaza, Onureg

Drug class: Antimetabolite

Mechanism of Action

Azacitidine is a pyrimidine nucleoside analog of cytidine and a hypomethylating agent (HMA). After cellular uptake and phosphorylation, it is incorporated into DNA and RNA strands where it traps DNA methyltransferases (DNMT1, DNMT3a, DNMT3b) in covalent complexes, causing their proteasomal degradation. This leads to global DNA hypomethylation, re-expression of silenced tumor suppressor genes (including p15/CDKN2B, p16/CDKN2A), and restoration of normal differentiation programs. At higher doses, direct cytotoxic effects from RNA and DNA strand incorporation also contribute.

FDA Indications

Common Side Effects

Clinical Pearl

Azacitidine requires a minimum of 4–6 cycles before declaring treatment failure, as responses are often delayed and the mechanism (epigenetic reprogramming) requires multiple cycles for gene re-expression. Approximately 17% of patients who initially achieve only stable disease will eventually convert to a complete or partial remission with continued therapy. The VIALE-A trial established azacitidine plus venetoclax as a new standard of care for AML patients ineligible for intensive…

Related Therapies & Mechanisms